Illumina Introduces Illumina SeqLab

Illumina Introduces Illumina SeqLab

Enables Customers to Quickly Scale to Population-size Production Capacity on HiSeq X Systems


Illumina, Inc. (ILMN) today announced the launch of Illumina SeqLab, an integrated solution for customers with HiSeq X™ Systems to enable large-scale human whole-genome sequencing operations. Designed to increase laboratory efficiency for population-scale, human whole-genome sequencing (HWGS), this new offering provides a complete solution for Illumina customers who need streamlined workflows with integrated sample tracking and fast and accurate analysis solutions. Illumina partnered with GenoLogics and Hamilton Robotics to provide this streamlined end-to-end solution which includes Clarity LIMS X Edition, Microlab® STAR™ liquid handling robotics, HiSeq® Analysis Software (HAS) v2.0 and Illumina SeqLab Consulting Service.

"This complete solution was important in our decision to purchase the HiSeq X System and to undertake population-scale whole-genome sequencing of large well-characterized cohorts in Scotland," said Professor David Hume, Director of The Roslin Institute at the University of Edinburgh, which provided funding along with the Biotechnology and Biological Sciences Research Council for the HiSeq X System to be installed in the Institute.

Professor Tim Aitman, Director of Clinical Genomics in Edinburgh Genomics at the University of Edinburgh, added, "Having access to the best-in-class tools and quick access to service gives us confidence that we can ramp up quickly and spend more time studying the genomes of cancer patients, children with rare diseases, and people with disorders of the central nervous system, while spending less time on setting up our sequencing center."

For laboratories that are new to population-level sequencing, developing and configuring the laboratory automation and software capabilities needed to process thousands of genomes per year can take significant resources and an extended period of time. The Illumina SeqLab plug-and-play solution helps laboratories maximize efficiency, optimize laboratory utilization and streamline analysis to enable maximum sample throughput in as little as six weeks. Moreover, it helps laboratories to deliver sequence results with confidence by enabling positive sample tracking throughout the laboratory process. As part of the service, expert consultants provide customers with detailed recommendations as they deploy Illumina's suite of world-class technologies, leveraging the company's more than 15 years of experience with genomics.

"The interest we've seen in population-scale sequencing as a result of the launch of the Illumina HiSeq X Ten Sequencing System last year and subsequent launch of the Illumina HiSeq X Five Sequencing System has far outpaced our expectations," said Illumina Senior Vice President of Life Sciences, Kirk Malloy. "With this new solution, we are enabling more laboratories to undertake large-scale sequencing programs by providing them with premium solutions to scale rapidly and maximize efficiency."

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit and follow @illumina.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

View source version on
Illumina, Inc.
Rebecca Chambers
[email protected]
Mina Nicoletti
[email protected]

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.